A listing of nabil-adra-md medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completingwo cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis with a standard acquisition protocol (as outlined in the protocol) as well as CT chest. A CThe abdomen and pelvis may be performed …
This is an open label randomized phase II trial of maintenance oral etoposide vs. observationwith relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood(PBSCT).
The main purpose of this phase 1 trial is to show that durvalumab is safe when given alone, in combination with BCG treatments, and in combination with radiation therapy. The overall goal of this trial is to see if the risk of your cancer coming back can be decreased with …
This is a study of perioperative pembrolizumab or enfortumab vedotin in combination withbrolizumab in participants who are cisplatin-ineligible or decline cisplatin withuscle-invasive bladder cancer (MIBC). The primary hypothesis is that perioperative pembrolizumab plus radical cystectomy (RC) plusvic lymph node dissection (PLND) and perioperative enfortumab vedotin in combination withbrolizumab plus RC+PLND …
A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose expansion Study to Evaluate they, Pharmacokinetics, and Anti-tumor Activity of ARX517 in Subjects with Advanced Solid Tumor with known PSMA Who Failed Prior Standard Therapies
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumabwed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed byvolumab with cabozantinib in patients with untreated renal cell carcinoma that has spreadher parts of the body. The addition of cabozantinib to the usual treatment may make …
The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib forwith incurable, refractory germ cell tumors. Patients will be treated until evidencedisease progression, non-compliance with study protocol, unacceptable major toxicity, atubject's own request for withdrawal, or if the study closes for any reason.
The purpose of this study is to compare any good and bad effects of using Atezolizumab along with the usual chemotherapy after progression with PD-1 or PD-L1 Inhibitor for individuals with urothelial carcinoma (cancer of the urinary tract).